Clinical Trials

34 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT04612530 2022-12-20

PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer

Phase 1 Unknown

18 enrolled

Pancreatic Neoplasms

NCT03682276 2022-12-13

PRIME-HCC

32 enrolled

Carcinoma, Hepatocellular

NCT05588297 2022-10-20

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

12 enrolled

Colorectal Cancer Liver Metastases

NCT04575922 2022-09-08

Nivolumab+Ipilimumab+RT in MSS mCRC

32 enrolled

Metastatic Microsatellite Stable Colorectal Cancer

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05213312 2022-06-15

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Phase 2/3 Unknown

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT05281926 2022-03-16

A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients

Phase 1 Unknown

10 enrolled

Carcinoma, Hepatocellular

NCT05162118 2022-03-09

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

51 enrolled

Advanced Pancreatic Cancer

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

176 enrolled

Carcinoma, Hepatocellular

NCT04233840 2022-01-27

P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

72 enrolled

Carcinoma, Hepatocellular

NCT04782791 2022-01-11

Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer

30 enrolled

Stomach Neoplasms

NCT02948348 2021-09-16

Study to Nivolumab Following Preoperative Chemoradiotherapy

90 enrolled

Rectal Neoplasms

NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Unknown

100 enrolled

Advanced Colorectal Carcinoma

NCT04503967 2020-08-07

OASIS

48 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04377048 2020-05-06

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

38 enrolled

Pancreatic Neoplasms

NCT03993626 2019-06-21

CAROSELL

55 enrolled

Colonic Neoplasms

NCT03784040 2019-04-08

da VINci

Phase 1 Unknown

40 enrolled

Stomach Neoplasms

NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

60 enrolled

GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

NCT03311789 2017-10-17

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

30 enrolled